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 ABSTRACT 
Glioblastoma (GBM) is known to be an extremely aggressive and malignant form of 
anaplastic arythrocytoma affecting the central nervous system in humans. Due to its worse 
prognosis leading to high mortality rate over the years , there is an urgent need to deviate 
from conventional surgical and radiation therapeutic treatments and delve into molecular 
targeted drug therapy techniques. Epiderma Growth Factor Receptor(EGFR) and its mutant 
version of EGFRvIII are known to be overexpressed case of GBM resulting in high rate of 
proliferation and failure in cell cycle arrest. EGFRvIII is expressed in about 62% of GBM 
cases and are self-activating receptors independent of ligands. This project is undertaken for 
the study of potential inhibitors for EGFRvIII mutant using bioinformatics tool. Thirteen of 
commercially available EGFR inhibitors were docked against EGFRvIII protein and stability 
of the docked results was based on their free binding energy values. The result was compared 
with that of Gefitinib and Erlotinib, the established inhibitors of EGFR.  PD153035, 
Lavendustin A and BIBX-1328BS were found to be the most suitable inhibitor for EGFRvIII 
, which can be proposed for wet-lab testing as molecular targeted drug therapy for GBM.   
Further, few structural modifications on two of these ligands were performed and in-silico 
docking analysis was repeated to check for more potential alternatives which can prove to be 
favourable inhibitors. 
Keywords : GBM (Glioblastoma Multiforme ), EGFRvIII (1I8I PubMed ID), in-silico 
protein-ligand docking. 
 
  
 
 
 
 
 
CHAPTER 1 
 
 
 
INTRODUCTION  
  
1. INTRODUCTION 
  
Among the cancers affecting the brain, Glioblastoma Multiforme (GBM) is the most 
commonly diagnosed. It is also established to be the most dangerous and aggressive form of 
primary neoplasm detected in central nervous system of humans [1] .GBM arises from the 
glial tissue of the brain (which include astrocytes, oligodendrocytes and ependymal cells). It 
has been studied that approximately 60% of the primary brain tumour detected are gliomas 
[2]. Gliomas are the neoplasms present in the CNS possessing different histological 
characteristics. Based on the similarities in the histological features between the malignant 
and the tumour cells, gliomas are broadly categorised into ependymomas, 
oligodendrogliomas and astrocytomas [3]. Astrocytomas are more prevalent in humans and 
GBM is its most common and aggressive form [4]. Unfortunately, GBM is more common in 
adult human males and has rather severe effect on brain than the spinal cord [5]. 
Generally, cancer consists of cells which continue to proliferate or divide when they are 
supposed to undergo apoptosis or cell cycle arrest. In most cancers, including GBMs, these 
kinds of molecular abnormalities are very prevalent. Now the signal for proliferation is 
specifically provided by a growth factor or ligand. Few important examples are TGF-alpha, 
platelet derived growth factor (PDGF) , epidermal growth factor(EGF) , vascular endothelial 
growth factor(VEGF) . These ligands interact with cells by the medium of receptors like EGF 
receptors, VEGF receptors and PDGF receptors. Activation of receptors is associated with 
cellular processes of mitosis or invasion into surrounding sites by upstream signal 
transduction cascades. But in case of cancer cells, these pathways show abnormalities in 
several levels. In 92% of astrocytoma, EGFR is overexpressed [6] and EGFRvIII, which is a 
mutant receptor capable of activation independent of any ligand, is expressed in up to 62% of 
GBMs [7].  
Certain receptors or molecular markers that are found overexpressed on malignant cells but 
are nearly absent in normal cells, act as potential drug targets. Hence, EGFRvIII is considered 
to be a novel target for pathological techniques. Studies suggest that EGFRvIII is 24% to 
65% overexpressed in GBM patients [8]. This mutated version is formed from EGFR by the 
genetic loss of its 270 amino acids.   
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GBM continues to remain associated with precarious prognosis [9][10]. While its 
insensitivity toward conventional chemotherapy treatments remains and the results of drug 
targeting due to the blood-brain barrier are more or less unsatisfactory [11][12], there is an 
urgent need for some results in the molecular therapeutic domains. This study adopts a 
cheminformatics based drug design approach to obtain few potential inhibitors against GBM 
from 16 non-specific EGFR inhibitors available for commercial usage. Comparative 
molecular docking experiments were undertaken between the ligands and EGFRvIII.  Based 
on their binding energies and other properties, the most potential drug-like molecules were 
obtained. Further docking experiments were performed  
The motive behind this study was to narrow down the most probable effective commercially 
available inhibitors against EGFRvIII. This stays an attempt to contribute to the molecular 
therapeutic studies being carried out for the treatment and an adept prognosis of GBM.  
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2. GLIOBLASTOMA MULTIFORME 
 
As it is known, cancers of brain are the consequence of abnormal growth of brain cells. From 
its origin, brain cancer can be divided broadly into two categories. First are the primary brain 
tumours. These mainly involve primary brain cells like gliomas, meningiomas, pituitary 
adenomas, vestibular schwannomas, primary CNS lymphomas, and medulloblastomas. 
Sometimes the site of cancers might be exclusive of brain but the tumour made of cancerous 
cells spread into brain by the bloodstream. These are known as metastatic brain tumour or 
secondary brain tumour. 
Glioma is a type of tumour that starts in the brain or spine and 60% of the primary brain 
tumour detected is gliomas .It derives its name from its association with the glial cells. These 
can be classified by cell types, grade and location. Gliomas resemble certain histological 
features with specific cell types , even though they need not necessarily originate from them. 
Based on this similarity gliomas are categorised as ependymomas (from ependyman cells), 
astrocytomas (from astrocytes) and oligodendrogliomas (from oligodendrocytes). Among 
these, astrocytomas are known to be most prevalent in humans. GBM is one of its most 
aggressive forms. Glioblastomas are also important brain tumour in canines and hence, 
research is being carried out to use this as a 
model for developing treatments in humans. 
GBM involves glial cells and accounts for 52% 
of all functional tissue brain tumour and 20% of 
all intracranial tumours.  
Based on the pathologic evaluation of the 
tumour, WHO (World health organisation) 
classified gliomas into four grade types: 
Grade I: this stage is referred when the tissue is 
benign and in the least advance stage. Best 
prognosis can be provided during this phase. 
Grade II:  this stage is referred when the 
gliomas are well differentiated (not anaplastic). 
Even though they are not benign, there are chances of better prognosis of patients. 
Figure 1.Coronal MRI with contrast of a 
GBM WHO grade IV in a 15-year-old male. 
figure 2. 1Coronal MRI with contrast of a 
GBM WHO grade IV in a 15-year-old male. 
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Grade III: this stage consists of anaplastic gliomas , which are highly malignant. Carrying 
out a prognosis is extremely difficult. 
Grade IV: the disease exists in its most advance stage and the prognosis is worse in this 
stage.  
Tentorium is a membrane present in the brain which seperates the cerebrum from the 
cerebellum. Based on the presence of the tumour above or below the tentorium, it is known as 
supratentorial and infratentorial respectively. Supratentorial gliomas persist mostly in adults 
(70%) and infraperitonial gliomas are majorly found in children.  
GBM has several regions of point mutations which establishes self-activating signal 
transduction pathways of the tyrosine kinase receptors [13] . EGFRvIII is one such mutation 
of EGFR when it loses 270 of its amino acids. EGFRvIII is overexpressed in about 62% of 
GBM cases studies. Due to these certain abnormalities GBM is seen to be resistant to 
conventional therapeutic treatments. GBM possess the inherent nature to diffuse 
topographically. This renders surgeries very unsatisfactory. The variable location of the 
tumour cell within the brain results in the inability to completely resect the tumour. Tumour 
cells has a tendency to migrate through brain parenchyma , get collected just below the pial 
margin and surround neurons and vessels to migrate through whit matter tracks [14]. 
Despite various multimodality treatment consisting of open craniotomy with surgical 
resection of maximum amount of tumour possible followed by chemoradiotherapy and 
symptomatic managements with corticosteroids, prognosis is extremely poor with a median 
survival time of approximately 14 months [15]. Most of the drug-targeted therapy remains 
unsuccessful as the blood brain barrier prevents the drug to reach their respective targets. 
During the last decade Temozolomide has come up chemotherapeutic drug that is able to 
cross the blood-brain barrier. Its effectiveness was studied in a large clinical trial consisting 
of 575 patients completely randomised. Comparative study was carried between patients 
treated by radiotherapy versus radiation plus temozolomide chemotherapy.  Results showed 
that group receiving temozolomide had median life of 14.6 months as opposed to 12.1 
months for group receiving radiation without temozolomide [16].  Although systematic 
chemotherapy benefited with improved results, an answer for long term disease control is yet 
to be devised. 
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3. EPIDERMAL GROWTH FACTORS 
RECEPTOR 
 
The epidermal growth factor receptor is the cell surface receptor member of EGF family 
protein ligands. It consist of four closely related tyrosine kinase receptors: 
EGFR(ErbB1),HER2/c-neu(ErbB2),HER3(ErbB3) and HER4(ErbB4). The receptor is 
present on the cell surface and is activated by the specific ligands like EGF and TGF-alpha. It 
functions by homo-dimerization with other family member which in turn activates its 
intrinsic intracellular protein-tyrosine kinase activity. The autophosphorylation of several 
tyrosine residues in EGFR activates signalling by several downstream proteins in signal 
transduction cascades, for example MAPK and JNK pathways. This leads to DNA synthesis, 
cell migration ,adhesion and proliferation. Any mutation that leads to EGFR over expression 
is directly associated with GBM.  This mutation leads to constant activation resulting in 
uncontrolled cell division. 
3.1 EGFRvIII (EPIDERMAL GROWTH FACTOR RECEPTOR Viii) 
 
EGFRvIII is a mutated variation of EGFR which often overexpressed in case of patients 
suffering from GBM. EGFR losses 270 of its amino acid 
residues to turn into this particular mutated version. 
EGFRvIII is capable of self-activation even in the 
absence of any ligand which might results in abnormal 
proliferation, metastasis and inhibition of cell death 
leading to a formation of an aggressive tumour.  
The PUBMED ID of EGFRvIII is 1I8I. EGFRvIII has in 
total 3 chains. These chains are represented by 3 
sequence unique entities. 
Below are the information about this protein obtained 
from PDB: 
CHAIN A:  EGFR Antibody MRISCFV light chain 
This is the first polymeric chain consisting of 107 
Figure 2  EGFRvIII mutant version. 
Courtesy PDB. Image is viewed using 
Jmol[19] 
3. 1EGFRvIII mutant version. 
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residues. It is light polymeric chain type. The PDB secondary structure of the protein   is 
given below 
 
 
Figure 3. 2Secondary structure of Chain A of EGFR vIII. Source PDB 
 
The secondary structure is 2% helical with 1 helices and 3 residues and 47% beta sheet with 
12 strands and 51 residues. 
CHAIN B : EGFR Antibody MRISCFV heavy chain  
This is the second polymeric chain consisting of  124 residues . It is  heavy polymeric  chain 
type. The PDB secondary structure of the protein   is given below 
 
 
Figure 3. 3Secondary structure of Chain B of EGFRvIII.Source PDB  
The secondary structure is 4%helical with 2 helices and 6 residues and 53% beta sheet 
structure with 11 strands and 66 residues 
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CHAIN C : EGFRvIII  peptide antigen 
 
 
 
Figure 3. 4Secondary structure of Chain   of EGFRvIII. Source PDB 
 
This is the third polymeric chain of the protein. It contains 12 residues. The PDB secondary 
structure of the protein   is given below 
The secondary chain has 8% beta sheet structure with 1 strand and 1 residue. 
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4. TOOLS FOR IN-SILICO STUDIES 
 
4.1 PROTEIN DATA BANK  
 
The PDB (protein data bank ) is  the single worldwide archive of structural data of Biological 
macromolecules, established in Brookhaven National Laboratories (BNL) in 1971. It contains 
Structural information of the macromolecules determined by X-ray Crystallography, NMR 
methods etc.  
4.2  PUBCHEM 
The PubChem compound database contains validated chemical depiction information 
provided to describe substances in PubChem Substance. Structures stored within  PubChem 
compounds are  pre-clustered and cross-referenced by identity and similarity groups. 
 
4.3 UCSF Chimera  
Chimera is developed by the Resource for Biocomputing, Visualization, and Informatics 
(RBVI) at the University of California,San Francisco, a program for interactive visualization 
and analysis of molecular structures.it helps us to obtain the structure either directly from the 
PDB site or through many other formats, to localize the ligand that is in the active site and 
display the docked structure. Secondary structure identification can be done, as it can show 
and hide ribbons. The secondary structure can oobserve motifs of the protein and also create a 
molecular surface around the protein, then colour the surface according to different properties 
of the amino acids. Studying the protein-ligans interaction canbe done by identifying the 
residues within 5.0A, and then identify the residues involved in the binding and label the 
residue names and types. Chimera shows the hydrogen bond interaction between proteins and 
ligands. 
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4.3.1 Energy Minimizations 
 Before energy calculations can be performed, it is necessary to correct structural 
inconsistencies, add hydrogen, and associate atoms with force field parameters. Clicking 
Minimize dismisses the dialog (unless the option to Keep dialog up after Minimize is 
checked) and may call Dock Prep to perform several tasks toprepare structure. Dock Prep 
may in turn call Add H and Add charge. Each of the tasks is a check-bx option that can be 
turned off independently if already done or deemed unnecessary. Minimization routines are 
performed by NMTK, which in included with Chimera. 
4.4 AUTODOCK 4.2  
(Link: http://autodock.scripps.edu/ ) 
AutoDock is an automated procedure or predicting the interaction of ligands with 
biomacromolecular targets. The motivation fo r this work arises from problems in the design 
of bioactive compounds, and in particular the field of computer-aided drug design. Progress 
in biomolecular x-ray crystallography allows accessto important protein and nucleic acid 
structures. These structures could be bioactive agents in the control of animal and plant 
diseases.  The study of precise interaction of such agents or candidate molecules with their 
targets is important in the developmental process. The goal of docking tools is the is to assist 
researchers in the determination of biomolecular compexes.  
In any docking scheme, two comflictin grequirements must be balanced: the desire for a 
robust and accurate procedure, and the desire to keep the computational demands at a 
reasonable level. The ideal procedure would find the global minimum in the interaction 
energy between between the substrate and the target protein, exploring all available degrees 
of freedom (DOF) for the system. AutoDock  combines two methods to achieve these goals: 
rapid grd-based energy evaluation and efficient search of torsional freedom[20]. 
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4.5 ACD/ChemSketch version 12.0  
(link : http://www.acdlabs.com/chemsketch/ ) 
ACD/ChemSketch is an integrated software package from Advanced Chemistry 
Development, Inc., developed to help chemists quickly and easily draw chemical structures, 
reactions, and schematic diagrams, calculate chemical properties, and design professional 
reports and presentations.  
ACD/ChemSketch includes:  
 Structure mode for drawing chemical structures and calculating their properties (for 
more information, refer to Section 3).  
 Draw mode or text and graphics processing (for more information, refer to Section 4).  
 Additional modules that extend the ACD/ChemSketch possibilities (most of them should 
be purchased separately).  
4.6 Q-SiteFinder  
 
Q-SiteFinder is a new method of ligand binding site prediction. It works by binding 
hydrophobic (CH3) probes to the protein, and finding clusters of probes with the most 
favourable binding energy. These clusters are placed in rank order of the likelihood of being a 
binding site according to the sum total binding energies for each cluster. 
It also gives the coordinates of the binding-box around selected sites. Binding box 
coordinates can be used as input for a docking program to ensure that ligands are only docked 
onto into the binding site.  
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5.  METHODOLOGY 
 
 
 
 
 
 
 
 
 
16 non-specific commercially 
available EGFR inhibitors 
listed 
protein preparation of 
molecular target of 
GBM ( EGFRvIII ) 
ligand structure 
preparation 
Binding site prediction 
for EGFRvIII 
protein-liagand 
docking using 
Autodock 4.2 
three complexes 
showing minimum 
binding energy were 
separated 
ananlysis of the 
corresponding ligand 
used 
modification of ligand 
using biosteric 
substituitions 
protein-ligand docking 
using modified ligands 
minimum binding energy comparison of 
complexes and best EGFRvIII inhibitor 
proposed 
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5.1 Ligand structure preparation  
 
The 16 non-specific commercially available EGFR inhibitors were listed. Its commercial 
usage was confirmed from a private retailer ChemCruz
TM
 Biochemicals , Santa Cruz 
Biotechnology Inc.  PubChem was used to download their chemical structures and other 
details and was viewed and converted into PDB file using Chimera.  Given below are the 
details of 16 inhibitors whose docking with EGFRvIII protein was analysed  
Table 5. 1LIST OF POTENTIAL EGFR INHIBITORS 
DETAILS OF LIGAND 
 
 
CHEMICAL STRUCTURE 
1. AG494  
PubChem compound  ID – 2055                         
Molecular  wt .- 280.28 
Molecular formula – C16H12N2O3  
2. AG555 
Pubchem compound  ID  –  5328770 
Molecular wt.- 322.36 
Molecular formula-   C19H18N2O3 
 
3. BIBX -1382BS 
 Pubchem compound ID – 6918505 
Molecular wt.- 496.80 
Molecular formula- C18H19CLFN7.2HCL.2H20 
  
4. DAPH   
Pubchem compound ID – 1697 
Molecular wt.- 329.4  
Molecular formula- C20H15N302 
E-value :  - 239.32  
5. ERBSTAIN ANALOG   
Pubchem compound ID – 5353609 
Molecular wt.- 194.0 
Molecular formula- C10H10O4 
 
6. LAVENDUSTIN A  
Pubchem compound ID – 3894 
Molecular wt.-  381.38 
Molecular formula- C21H19NO6  
E-value :  -240.72  
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7. LAVENDUSTIN B   
Pubchem compound ID – 3895 
Molecular wt.- 365.4  
Molecular formula- C21H19NO5  
 
8. PD 153035   
Pubchem compound ID –  4705  
Molecular wt.-  360.21  
Molecular formula-  C16H14BrN3O2  
 
 
9. RG 13022   
  Pubchem compound ID –  5468216  
  Molecular wt.-  266.3  
Molecular formula- C16H14N2O2 
 
 
10. Tyrophostin 47   
Pubchem compound ID – 5485187  
Molecular wt.-  220.2  
Molecular formula-   C10H8N2O2S  
11. TYROPHOSTIN AG99   
Pubchem compound ID –  5328567  
Molecular wt.- 204.18  
Molecular formula- C10H8N2O 
 
 
12. TYROPHOSTIN 51  
Pubchem compound ID –  5328807 
Molecular wt.- 268.2  
Molecular formula-  C13H8N4O3 
  
13. TYROPHOSTIN  AG 183   
Pubchem compound ID –  5328807 
Molecular wt.- 268.2 
Molecular formula-  C13H8N4O3 
 
 
14. TYROPHOSTIN AG1478   
Pubchem compound ID – 2051 
Molecular wt.- 315.76  
Molecular formula- C16H14ClN3O2 
 
 
15. TYROPHOSTIN B44(-) 
 Pubchem compound ID –   5328772  
Molecular wt.-  308.3  
Molecular formula-  C18H16N2O3 
 
 
16. TYROPHOSTIN RG 14620  
 Pubchem compound ID – 5926218  
Molecular wt.- 275.14 
Molecular formula-  C14H8Cl2N2 
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5.2 Binding site prediction for EGFRvIII 
 
The most probable ligand binding site of 1I8I was determined using the Q-SiteFinder 
version2.3[18] as the active sites for EGFRvIII was not well defined in PDB. The SiteMap 
predicts a suitable binding site by the following three steps : 
 Initially a grid is assigned and all the points are grouped into sets depending on 
several criterias used to define sites 
 The corresponding sites are then mapped on another grid and  visual files of the maps 
are produced 
 Finally, all the properties are evaluated and the different sites are written in maestro-
readable form. Every step is compiled by an impact job and hence the best site is 
considered for usage in docking studies. 
21 | P a g e  
 
 
Figure 5. 1Screenshot of Q-site finder 
 
 
5.2 Protein preparation of molecular targets of GBM 
 
Protein-ligand docking was conducted on three dimensional (3D) structures of EGFRvIII 
molecular target of GBM (PDB ID 1I8I). This structures was obtained from protein data 
bank[17]. Prior to the docking, hydrogen atoms were added to the crystal structure of 1I8I 
and the structure was minimized by addition of required Gasteiger charges using 
AutoDock4.2v.All the missing loops were filled. Charge field was set up and   extra 
Hydrogen atom was added and all unwanted water molecules was removed. 
Total Gasteir charges added = 0.002 
Total Kollman charges added = -67.7 
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5.3 Docking Using AutoDock 4.2  
 
As mentioned earlier, docking with AutoDock follows three important steps : 
1. Preparation of receptor & ligand files. 
2. Calculation of affinity maps by using a 3D grid around the receptor & ligand. 
3. Defining the docking parameters and running the docking simulation. 
The preparation step starts with pdb files of receptor (R.pdb) and ligand (L.pdb), which are 
added with hydrogen and then saved as RH.pdb & LH.pdb. The calculation of affinity maps 
in the "Grid" section requires the above pdb files to be assigned charges & atom types, and 
also that the nonpolar hydrogens are merged. This is done automatically by ADT, and the 
resulting files are saved as RH.pdbqt & LH.pdbqt, which is the only format AutoGrid & 
AutoDock can work with. Calculation of affinity maps is done by AutoGrid, and then 
 
Figure 5. 2Minimized structure of EGFRvIII prior to docking using 
Autodock 
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docking can be done by AutoDock. The newest docking algorithm is LGA (Lamarckian 
Genetic Algorithm). 
 
Figure 5. 3 Screenshot of the files during docking process 
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Figure 5. 4 ScreenShot during Docking using AutoDock4.2 
  
5.4 Modification of ligands structure 
 
The three ligands forming the most stable complexes with minimum binding energies are 
choosen for further analysis. The structure of the ligands were modified in an attempt to 
derive better inhibitor to the receptor. Some of the alterations considered were tautomeric 
transforms and bioisotertic substitutions.  
Tautomeric transforms of the ligand were checked using Chemsketch 12.0.  
Bioisosteric substitution is the process of starting withand intital active compound and 
replacing functional groups with other groups that have similar biological properties. Unlike 
isosteres, which have the same number and arrangement of electrons, bioisosteres are 
selected based on having a similar electronegativity, steric size , lipophilicity and other 
properties that affect the way in which drug binds to the target. 
Monovalent Groups : H, F , Cl, Br, I, OH, SH, NH2, SCH3, PH2, CH3, i-Pr, t-Bu, OCH3. 
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6. RESULTS AND DISCUSSIONS 
 
6.1 MINIMIZATION OF PROTEIN  
 
First step prior to docking process is the minimization of the protein. So after the PDB file of 
1I8I (EGFRvIII) was downloaded , its minimization was done as follows: 
Addition of Hydrogen Atoms  = 0 
Addition of Kollman Charges = -67.7 
Addition of Gasteiger Charges =0.0002 
Following figure shows the molecule before and after minimization was performed. 
                 
Figure 6. 1 EGFRvIII (a) before minimization (b) after minization 
 
6.2 PROTEIN BINDING SITE  
 
Protein binding site prediction using Q-Site Finder, gave 10 probable sites of ligand binding. 
These are the site which might be used by the docking programs before providing the best 
docking site and the corresponding result. 
(a) (b) 
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The Q-SiteFinder predicted the following: 
Predicted site: 1  
Site Volume; 152 Cubic 
Protein volume: 20557 cubicA 
Binding box around selected site: 
Min Coordinate: (-3, 20, 19) 
Max Coordinate.: (13, 35, 33) 
Therefore, Central coordinates to be used as a input in the docking studies is (5, 27.5, 21) 
All of the protein atoms close to a probe-cluster defining a site are listed below. The atom 
number, atom type, residue name, chain identifier and residue number are given 
340  CA  LYS A  45   
  341  C   LYS A  45   
  343  CB  LYS A  45   
  344  CG  LYS A  45   
  345  CD  LYS A  45   
  346  CE  LYS A  45   
  347  NZ  LYS A  45   
  348  N   PHE A  46   
  349  CA  PHE A  46   
  350  C   PHE A  46   
  351  O   PHE A  46   
  352  CB  PHE A  46   
  353  CG  PHE A  46   
  354  CD1 PHE A  46   
  356  CE1 PHE A  46   
  418  CA  ARG A  55   
  419  C   ARG A  55   
  420  O   ARG A  55   
  421  CB  ARG A  55   
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  422  CG  ARG A  55   
  423  CD  ARG A  55   
  424  NE  ARG A  55   
  425  CZ  ARG A  55   
  426  NH1 ARG A  55   
  428  N   PRO A  56   
  429  CA  PRO A  56   
  430  C   PRO A  56   
  431  O   PRO A  56   
  432  CB  PRO A  56   
  433  CG  PRO A  56   
  434  CD  PRO A  56   
  439  N   VAL A  58   
  443  CB  VAL A  58   
  445  CG2 VAL A  58   
 
 
Figure 6. 2 Probable binding site of EGFRvII using Q-Site Finder 
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6.3 RESULTS OF  DOCKING IN AUTODOCK4.2 
 
  After the docking was performed using AutoDock4.2 which calculated the free binding 
energy values for each protein-ligand complex formed, the stability of the inhibitor-receptor 
binding was studied on the basis of relative low binding energy of the complex. Below shown 
are the  conformational clustering histograms for all the protein-ligand complex.
 
(a) 
 
(b) 
(c) 
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(d) 
(e) 
(f) 
(g) 
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(h) 
(i) 
(j) 
(k) 
32 | P a g e  
 
(l) 
(m) 
(n) 
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Figure 6. 3 Binding Energy Plots of (a)PD153035 (b)AG555  (c)BIBX-1328BS (d) 
lavendustin A (e ) RG13022 (f) erbstatinanalog (g)tyrophostin 47 (h)DAPH (i) Lavendustin B 
(j)tyrophostin 51 (k) AG494 (l)tyrophostin AG99 (m) tyrophostin AG183 (n) tyrophostin 
RG14620 (o) erlotinib (p)gefitinib  
 
Table 6. 1 Free Binding Energy values of the Docked Complexes and the corrsponding 
Ligand used 
 
 
LIGAND 
 
FREE BINDING ENRGY IN 
Kcal/Mol 
 
 
AG494  -4.77 
TYROPHOSTIN AG999 -5.11 
ERBSTAIN ANALOG -5.58 
TYROPHOSTIN 47 -4.93 
RG 13022 -4.63 
TYROPHOSTIN 183 -5.19 
TYROPHOSTIN 51 -5.06 
(o) 
(p) 
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DAPH -4.77 
LAVENDUSTIN B -6.56 
LAVENDUSTIN A -4.41 
BIBX-1382BS -7.9 
PD 153035 -8.98 
ERLOTINIB -5.15 
GEFITINIB -4.52 
  
  
 
For a precise comparative study of the free binding energies of the complexes formed , the 
above result was plotted in a graph. 
 
Figure 6. 4 Graph showing the comparative Free Binding energy plots of the ligands 
By comparing all the free binding energies in case of each ligand , the most favourable 
ligands forming the docked structures were : 
 PD153035  
 LAVENDUSTIN A 
 BIBX -1382BS 
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Figure 6. 5 . Docked complex with PD153035 
              
     
Figure 6. 6 Docked Complex with Lavendustin A 
              Figure 15. Docked Complex with Lavendustin A 
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Figure 6. 7 . docked Complex formed with BIBX-1328BS 
 
6.6 MODIFICATION OF THE LIGAND STRUCTURE 
 
Several modifications were done on the three most stable ligands which were obtained from 
docking with 1I8I using HEX6.3. ChemSketch was used to modify the structures. It was on 
basis of finding tautomeric structures and performing biosteric substitutions. 
However, Chemsketch showed that the molecules were already in its most stable tautomeric 
form. Hence, monovalent groups of the structure were changed in an attempt to derive a 
structure capable of providing a more stable docking with 1I8I. 
Modifications    
PD153035 
Some of  the monovalent Bioisters are  H, F, Cl, Br, I , -OH, -SH, -NH2, -SCH3, -PH2, -CH3,  
i-Pr, t-Bu . All these groups contains similar electronegativity, steric size ,lipophilicity and 
other properties that affects the way in which drug binds to the target. 
The bromide monovalent group was substituted with t-butyl group and the following structure 
was obtained. let’s say M1. 
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Figure 6. 8 PD15303 . Source PDB 
  
 
 
Figure 6. 9 Modified structure, drawn using   ChemSketch. M1 
  
            
Further one of the ether group (-OCH3) was substituted with methyl group, lets say M2 
 
Figure 6. 10 Modified structure drawn using ChemSketch. M2 
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BIBX-1328BS  
 
Figure 6. 11 modified structure using ChemSketch. (B1) 
 
 
6.7 DOCKING WITH THE MODIFIED STRUCTURES  
 
The free binding energy value calculated after docking of M1 and M2 with 1I8I using Auto 
Dock  was calculated to be  -8.39Kcal/Mol and – 8 .21Kcal/mol . This shows that, these 
structural modifications might share similar properties as PD153035.  
However , when this particular structure was docked , the binding energy value was not as 
favourable as in the previous case.  Results showed it to be -4.1 Kcal/Mol 
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7. CONCLUSION 
 
 By performing in-silico protein-ligand docking analysis of 16 non-specific inhibitors of 
EGFR with EGFRvIII receptors, this was an attempt to propose the most suitable 
commercially available EGFR inhibitors which can prove to be effective for targeting 
EGFRvIII mutant. Results showed that PD 153035, BIBX-1382BS and LAVENDUSTIN B 
formed protein-ligand complex with the least free binding energy, showcasing higher stability 
of the molecule formed as compared to the rest of the ligands. It was in fact observed that 
these ligand formed more stable complexes with the specific EGFRvIII mutant in comparison 
to  Gefitinib and Erlotininb - the widely used EGFR inhibitors for molecular targeted cancer 
therapy. Further, biosteric substitutions were performed on these favourable inhibitors for 
structural modifications and in-silico protein-ligand docking was repeated with the modified 
structure. complexes showed free binding energy in the favourable range, leadin us to 
conclude that these few structures were could be proposed for further wetlab analysis inorder 
to study there detailed effect as molecular targeted drug therapy for treating Glioblastoma.   
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